PCOS as metabolic disorder
PCOS was historically defined by reproductive features, irregular cycles, ovarian cysts on imaging, and hyperandrogenism (high androgens). The Rotterdam criteria require any 2 of 3: anovulation, clinical/biochemical hyperandrogenism, polycystic ovaries.
What this definition obscures is the metabolic core of the disease for most patients. The majority of PCOS patients have insulin resistance, hyperinsulinemia, and central adiposity. The high insulin drives ovarian androgen production. The androgens drive the reproductive features. The metabolic dysfunction is causal, not just associated.
PCOS phenotypes
Different PCOS phenotypes exist:
- Classic PCOS, central obesity, insulin resistance, irregular cycles, hyperandrogenism, hirsutism, acne
- Lean PCOS, normal BMI but visceral adiposity, insulin resistance, hyperandrogenism
- Ovulatory PCOS, regular cycles but androgen elevation and metabolic features
- Non-hyperandrogenic PCOS, anovulation and polycystic ovaries without androgen excess
Most phenotypes share a metabolic core. Lean PCOS is sometimes confusing because BMI is normal, but visceral fat and insulin resistance can still be present.
Insulin as the driver
The mechanistic chain in classic PCOS:
- Insulin resistance develops, often genetically driven and amplified by environment
- Compensatory hyperinsulinemia results
- High insulin stimulates ovarian theca cells to produce androgens
- High insulin reduces hepatic SHBG production, increasing free testosterone
- High androgens disrupt follicle maturation, causing anovulation
- Anovulation produces irregular cycles and infertility
- Androgens cause hirsutism, acne, scalp hair thinning
Treating the metabolic root unwinds the cascade.
Trial data on GLP-1
Multiple PCOS-specific trials of semaglutide and tirzepatide:
- Substantial weight loss (15-20% on tirzepatide, 12-17% on semaglutide)
- Testosterone reduction 20-35%
- SHBG increase
- Free androgen index reduction substantial
- Menstrual regularization in 60-80%
- Restored ovulation in similar proportion
- Reduced fasting insulin and HOMA-IR
- Improved acne and hirsutism scores
- Improved fertility outcomes in patients trying to conceive
The improvement cascade
Patient-experienced cascade over months:
- Months 0-3: Weight starts dropping, cycles may begin to regularize, energy improves
- Months 3-6: Testosterone drops, acne improves, hair shedding may briefly worsen then improve, periods more regular
- Months 6-12: Ovulation often resumes, fertility restored, mood improvements common
- Year 1+: Sustained metabolic benefits compound
Fertility implications
For patients trying to conceive, restored ovulation often leads to spontaneous pregnancy. The "Ozempic baby" phenomenon is concentrated in PCOS patients. Patients who don't want pregnancy need reliable contraception. Patients who do want it should plan a coordinated stop with their provider before active conception attempts. GLP-1 and fertility covers stop timing.
What to monitor
For PCOS patients on GLP-1 therapy:
- Total and free testosterone
- SHBG
- Fasting insulin, HbA1c, glucose
- Lipid panel
- hs-CRP
- Liver enzymes (PCOS often co-occurs with NAFLD)
- Vitamin D (often low in PCOS)
- Cycle tracking
OPTML's hormone and metabolic panels capture this comprehensively.
The clinical insight: PCOS is a metabolic disorder for most patients. Treating the metabolic root with GLP-1 therapy unwinds the reproductive cascade. The combination of weight loss, insulin sensitization, and reduced androgens produces transformations that often exceed what any other PCOS treatment achieves.
Bottom line
For most PCOS patients, the disease is fundamentally a metabolic disorder driven by insulin resistance and hyperinsulinemia. GLP-1 therapy targets the metabolic root and produces a cascade of improvements, testosterone reduction, cycle regularization, restored ovulation, improved acne and hirsutism, restored fertility. It's increasingly considered first-line metabolic treatment for PCOS alongside lifestyle intervention.